Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a clinical-stage biopharmaceutical company with a strong pipeline of targeted combination therapies for high unmet medical needs, focused on improving outcomes for cancer patients undergoing treatment. The company's patented Trans-Arterial Micro-Perfusion therapy platform has the potential to minimize toxicities associated with traditional cancer therapies and its lead drug, RenovoGem, is in a Phase 3 registration trial for the treatment of Locally Advanced Pancreatic Cancer. With a large market potential, strong progress in clinical development and commercialization efforts, and a solid balance sheet, RenovoRx is well-positioned for future success and potential revenue growth.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company with a focus on developing combination therapies for cancer patients. While recent interim analysis results and the addition of a new CFO may provide some positive momentum, the company's current revenue of only $0.2 million and consistent net losses highlight the high risks and slow progress of its drug development. Additionally, although the potential market for pancreatic cancer treatment is large, there are multiple risks that could prevent the company from successfully commercializing its products and reaching its target share price.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.